Oncolytics Biotech (ONC) Competitors

Oncolytics Biotech (TSE:ONC) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership.

Do institutionals and insiders believe in ONC or MDNA?

7.0% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 7.9% of Medicenna Therapeutics shares are held by institutional investors. 6.2% of Oncolytics Biotech shares are held by company insiders. Comparatively, 23.7% of Medicenna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Is ONC or MDNA more profitable?

Medicenna Therapeutics' return on equity of -59.47% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-102.66%	-55.47%
Medicenna Therapeutics	N/A	-59.47%	-34.57%

Do analysts prefer ONC or MDNA?

Oncolytics Biotech currently has a consensus target price of C$6.00, indicating a potential upside of 308.16%. Given Oncolytics Biotech's higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than Medicenna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Medicenna Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Which has more volatility and risk, ONC or MDNA?

Oncolytics Biotech has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Comparatively, Medicenna Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.

Does the MarketBeat Community favor ONC or MDNA?

Oncolytics Biotech received 108 more outperform votes than Medicenna Therapeutics when rated by MarketBeat users. Likewise, 75.38% of users gave Oncolytics Biotech an outperform vote while only 68.22% of users gave Medicenna Therapeutics an outperform vote.

Company	Underperform	Outperform
Oncolytics Biotech	Outperform Votes 196 75.38%	Underperform Votes 64 24.62%
Medicenna Therapeutics	Outperform Votes 88 68.22%	Underperform Votes 41 31.78%

Which has better earnings and valuation, ONC or MDNA?

Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-C$27.75M	-C$0.41	-3.59
Medicenna Therapeutics	N/A	N/A	-C$15.42M	-C$0.23	-10.83

Does the media prefer ONC or MDNA?

In the previous week, Medicenna Therapeutics had 4 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Medicenna Therapeutics and 0 mentions for Oncolytics Biotech. Medicenna Therapeutics' average media sentiment score of 0.54 beat Oncolytics Biotech's score of -0.88 indicating that Medicenna Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oncolytics Biotech	Negative
Medicenna Therapeutics	Positive

Summary

Medicenna Therapeutics beats Oncolytics Biotech on 8 of the 14 factors compared between the two stocks.